Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation

Neoplasia

Volumn 8, Issue 10, 2006, Pages 817-825

  Ogata, Yoshitaka ^a   Osaki, Tadashi ^a   Naka, Tetsuji ^a   Iwahori, Kota ^a   Furukawa, Mitsugi ^a   Nagatomo, Izumi ^a   Kijima, Takashi ^a   Kumagai, Toru ^a   Yoshida, Mitsuhiro ^a   Tachibana, Isao ^a   Kawase, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Drug resistance; Lung cancer; PI3 K Akt; Protein inhibitor of activated STAT (PIAS) 3; Suppressors of cytokine signaling (SOCS) 3

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR OF ACTIVATED STAT3; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 33749858519     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.06409     Document Type: Article

References (37)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, and Thun MJ (2004). Cancer statistics, 2004. CA Cancer J Clin 54, 8-29.
2. Belani CP and Langer C (2002). First-line chemotherapy for NSCLC: an overview of relevant trials. Lung Cancer 38 (4), 13-19.
3. Boulikas T and Vougiouka M (2004). Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep 11, 559-595 (Review).
4. Cortes-Funes H (2002). New treatment approaches for lung cancer and impact on survival. Semin Oncol 29, 26-29.
5. Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, et al. (2005). Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 11, 6414-6421.
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139.
7. Buettner R, Mora LB, and Jove R (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8, 945-954.
8. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, and Tweardy DJ (1998). Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102, 1385-1392.
9. Vignais ML, Sadowski HB, Watling D, Rogers NC, and Gilman M (1996). Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol 16, 1759-1769.
10. Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, and Shuai K (1997). Specific inhibition of Stat3 signal transduction by PIAS3. Science 278, 1803-1805.
11. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, et al. (1997). Structure and function of a new STAT-induced STAT inhibitor. Nature 387, 924-929.
12. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, et al. (1997). A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387, 921-924.
13. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, et al. (1997). A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921.
14. Shen SH, Bastien L, Posner BI, and Chretien P (1991). A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 352, 736-739.
15. Rakesh K and Agrawal DK (2005). Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 70, 649-657.
16. Wormald S and Hilton DJ (2004). Inhibitors of cytokine signal transduction. J Biol Chem 279, 821-824.
17. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, and Jablons DM (2003). SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100, 14133-14138.
18. Wu C, Sun M, Liu L, and Zhou GW (2003). The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306, 1-12.
19. Bromberg J (2002). Stat proteins and oncogenesis. J Clin Invest 109, 1139-1142.
20. Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T, and Wasik MA (2002). Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 168, 466-474.
21. + efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem 277, 17852-17862.
22. Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y, Takamori K, Tokuda C, and Saito I (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 93, 1320-1324.
23. Kijima T, Osaki T, Nishino K, Kumagai T, Funakoshi T, Goto H, Tachibana I, Tanio Y, and Kishimoto T (1999). Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res 59, 4906-4911.
24. Kanegae Y, Makimura M, and Saito I (1994). A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 47, 157-166.
25. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, and Kishimoto T (1994). Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54, 5258-5261.
26. Inoue K, Yoshida M, Arai T, Hoshino S, Yano Y, Yanagita M, Kida H, Takimoto T, Hirata H, Kumagai T, et al. (2005). IL-10 inhibits transforming growth factor-β-induction of type I collagen mRNA expression via both JNK and p38 pathways in human lung fibroblasts. EXCLI J 4, 49-60.
27. Sordella R, Bell DW, Haber DA, and Settleman J (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167.
28. Battle TE and Frank DA (2002). The role of STATs in apoptosis. Curr Mol Med 2, 381-392.
29. Oki S, Limnander A, Danial NN, and Rothman PB (2002). Functional involvement of Akt signaling downstream of Jak1 in v-Abl-induced activation of hematopoietic cells. Blood 100, 966-973.
30. Wang L and Banerjee S (2004). Differential PIAS3 expression in human malignancy. Oncol Rep 11, 1319-1324.
31. Schmidt D and Muller S (2003). PIAS/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci 60, 2561-2574.
32. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, and Nunez G (1997). Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689.
33. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, and Reed JC (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321.
34. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, and Johnson SW (2005). Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92, 1149-1158.
35. Brognard J, Clark AS, Ni Y, and Dennis PA (2001). Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61, 3986-3997.
36. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, and Fan Z (2003). HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22, 3205-3212.
37. Dreuw A, Hermanns HM, Heise R, Joussen S, Rodriguez F, Marquardt Y, Jugert F, Merk HF, Heinrich PC, and Baron JM (2005). Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol 124, 28-37.